common pathological feature in myocardial ischemia (MI) (Ling and Lou 2005) . It has been reported that Akt activity reduces apoptosis, infarction, or cardiac dysfunction during cardiac ischemia injury or ischemia-reperfusion injury (Matsui et al. 1999 (Matsui et al. , 2001 Fujio et al. 2000) . Akt is necessary and sufficient for inhibition of apoptosis in cardiomyocytes (Aikawa et al. 2000; Fujio et al. 2000; Negoro et al. 2001; Yamashita et al. 2001) . Activated Akt kinase plays a central role in suppressing myocardial apoptosis by modulating the activities of Bcl-2 family proteins, in the release of mitochondrial cytochrome c, and activation of cytosolic caspases (Takatani et al. 2004) .
Guanxin II (GXII) is a well-known traditional Chinese formula to treat coronary heart disease (CHD) in China. It contains Salvia miltiorrhiza Bge., Carthamus tinctorius L., Paeonia lactiflora Pall., Ligusticum chuanxiong Hort. and Dalbergia odorifera T. Chen in a ratio of 2:1:1:1:1 ). In recent studies, GXII showed the effects of anti-ischemia (Zeng et al. 2008) , anti-apoptosis (Zhao et al. 2007 (Zhao et al. , 2008 Huang et al. 2009 ) and anti-oxidation ). However, little is known about GXIIinduced antiapoptosis via the Akt-survival signaling pathway. What's more, the rat dose of GXII (2.5 g/kg) in the present study was converted according to the Pharmacopeia of China (24 g/day in human). That is, the rat is 6.7 times the doses of human (Pinkel 1958) . The tested doses of all these published studies mainly focused on 5~30 g/kg (Zhao et al. 2007 (Zhao et al. , 2008 Huang et al. 2009; ). Thus, it was important to perform the studies in ≤ 2.5 g/kg of GXII.
The purpose of the present research was to evaluate whether or not GXII at 0.5 or 2.5 g/kg could protect the heart against myocardial apoptosis in rats with MI. If so, we would investigate whether the antiapoptotic mechanisms of GXII are related to the Akt pathway.
Materials and Methods

Preparation of GXII
GXII formula extracts were prepared as previously described ). All of the herbs were purchased from West China Hospital (Chengdu, China). They were also identified by the herbal medicine botanist Professor Z.H. Hu (Department of Botanical Anatomy, Northwest University, Xi'an, China). GXII was boiled twice in distilled water (1:12, w/v) for 30 min. The blended supernatants were then lyophilized, and stored at 4°C until use. According to the high-performance liquid chromatography (HPLC) method used (Zhao et al. 2007) , the contents of each component in GXII (mg/g, n = 3) were: tanshinol 0.704 ± 0.007, protocatechualdehyde 0.015 ± 0.0005, peoniflorin 3.715 ± 0.131, hydroxysafflor yellow A 2.067 ± 0.017, and ferulic acid 0.129 ± 0.001.
Experimental protocol
Experiments using rats obtained from the Shanghai Laboratory Animal Center (Shanghai, China) conformed to the Regulations for the Administration of Affairs Concerning Experimental Animals (1988) . The experimental protocol was approved by the Animal Experimental Center for West China Hospital, Sichuan University (Chengdu, China). Male adult Sprague-Dawley rats (200-250 g) were housed in conventional cages. Rats were randomly assigned into four groups: (i) MI + vehicle group, rats were given 20 mL/kg/day of 0.9% NaCl for 15 days; (ii) sham MI group, rats were given 20 mL/kg/day of 0.9% NaCl for 15 days; (iii) MI + GXII 2.5 g/kg group, rats were given 20 mL/kg/day of 12.5% GXII for 15 days; and (iv) MI + GXII 0.5 g/kg group, rats were given 20 mL/kg/day of 2.5% GXII for 15 days. Administration was via the oral route, and was once a day for 15 consecutive days. Thirty min after the last dose, the left anterior descending coronary artery was occluded except for sham-operated rats.
Surgical preparation
Rats were anesthetized with sodium pentobarbital (40 mg/kg, i.p.), and ventilated with room air (tidal volume, 3 mL/100 g; respiratory rate, 68 cycles/min) using an animal respirator (DH-150, Chengdu, China). A thoracotomy was done in the fourth intercostal space on the left side and the heart was exposed. The pericardium was opened and a 1.0 silk suture placed around the left anterior descending coronary artery close to its origin. The coronary artery was then occluded. Sham-operated rats were subjected to the same procedures without coronary artery ligation. The operation time was about 10 min, and the mortality was 9% in each group. Hearts were harvested at the end of a 3-h ischemic period for measurement of the number of apoptotic cardiomyocytes; Akt activation; expression of Bcl-2 and Bax protein; release of cytochrome c; and activity of caspase-3 and caspase-9. Infarct size over a 24-h ischemic period was also evaluated. Myocardial blood flow (MBF) was determined at the end of a 2-h ischemic period to elucidate the mechanism of GXII.
MBF measurement
Fluorescent microspheres 10 µ m in diameter (FluoSpheres ® ;
Invitrogen, Carlsbad, USA) were used to measure MBF in the area at risk (RA; the ischemic zone) and the remote control area (CA; the non-ischemic zone) of the heart of acute MI rats 2 h after the last oral administration of GXII (2.5 g/kg, n = 12), and vehicle (n = 10) and sham-operated groups (n = 10) for 15 days, as described previously (Thibault et al. 2005 ). Rats were killed and the heart excised. 
Determination of Infarct size
The determination was carried out according to the method (Zhao et al. 2007) . At the end of the 24-h ischemic period, Evans blue dye was injected into the aortic root to stain the normally perfuse region blue and outline the area at risk (AAr). After freezing at -20°C, the heart was sliced into 1 mm-thick transverse sections. The AAr was separated from the non-ischemic zone and incubated at 37°C for 10 min in a 1% solution of triphenyltetrazolium chloride (SCR, Shanghai, China) to differentiate necrotic (pale) from non-necrotic (red) AAr. The AAr as a percentage of the left ventricle (Lv) (i.e., AAr/Lv), and the area of necrosis (An) as a percentage of the AAr (i.e., An/AAr) were calculated.
Determination of the number of apoptotic cells
Apoptotic myocytes were quantitatively detected by terminal deoxy-nucleotidyl transferase mediated dUTP nick end-labeling (TUNEL) assay using a Cell Death Detection Kit (Roche Molecular Biochemicals, USA) with manufacturer's protocol. The AAr myocardium was embedded in a paraffin block and serial slides of 4-5 µ m thicknesses cut from each tissue block on slides. Sections were de-waxed, immersed in xylene, and sequentially rehydrated. Sections were treated with protein K (Amresco, USA). Tissue sections were incubated with TUNEL reaction mixture and non-specific binding sites blocked. Slides were covered with the mounting medium containing 4´, 6-diamidino-2-phenylindole (DAPI) to permit counting of the total number of nuclei. After two washes, samples were photographed using an Epi-illumination microscope (Olympus IX71, Japan) at the same magnification (× 400). Image-Pro Plus software (version 6.0u, USA) was used to determine the number of positive cells and the total number of cells. For each slide, ten fields were randomly chosen and the index of apoptosis determined in a blinded manner.
Immunohistochemical assay
Myocardial left ventricular samples were embedded in a paraffin block and serial slides of 4-5 µ m thickness cut. The sections were de-waxed and hydrated. They were then incubated with 3% H 2 O 2 for 30 min, 0.01 mol/L citric acid solutions for 5 min, and 5% non-fat milk for 20 min. Thereafter, sections were incubated overnight at 4°C with primary antibodies (rabbit anti-Bcl-2 and anti-Bax (1:400); Santaz, USA) and then incubated with diluted biotinylated secondary antibody (Santaz, USA) for 30 min. Diaminobenzidine (DAB) was used for development. Slides were counterstained with hematoxylin, then dehydrated, cleared and covered. Finally, samples were photographed using a microscope (Bino Photo, Japan) at the same magnification (× 400). Positive (brown) cardiac myocytes were regarded to be apoptotic cells. Image-Pro Plus software was used to analyze the Bcl-2/Bax ratio.
Preparation of mitochondrial/cytosolic fractions
Preparation of mitochondrial and cytosolic fractions was achieved using a commercially available Cytochrome c Releasing Apoptosis Assay Kit (Bio Vision, USA) according to the manufacturer's protocol. Frozen myocardial left ventricular samples were homogenized in ice-cold lysis buffer using a glass-glass homogenizer (DY89-1, Chengdu, China). The homogenates of samples were centrifuged at 700 × g for 10 min at 4°C. Resuspended cells were centrifuged at 10,000 × g for 30 min. The supernatant was the cytosolic fraction. The cell pellet was resuspended in Mitochondrial Extraction Buffer Mix and served as the mitochondrial fraction. Protein concentrations were determined using a Protein Assay Kit (Zhong ShanGolden Bridge Biotechnology, China) as a standard.
Western blots
Proteins from the mitochondrial fraction (cytochrome c) and cytosolic fraction (cytochrome c, total Akt, phosphorylated Akt (p-Akt)) were resolved by 12% and 5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, USA). The PVDF membranes were incubated with the specific primary antibody to cytochrome c (dilution, 1:300; Santa Cruz Biotechnology, Santa Cruz, USA), total Akt (dilution, 1:800; Cell Signaling Technology, Beverly, MA, USA) and p-Akt at residues Ser473 (dilution, 1:500; Cell Signaling Technology, Beverly, MA, USA). Membranes were then incubated with goat anti-mouse or goat anti-rabbit secondary antibodies (dilution, 1:20000; Zhong Shan-Golden Bridge Biotechnology, Beijing, China). Thereafter, proteins were visualized using an electrochemiluminescence detection system (Lucky, China) with 5-10-min exposure in a dark room and analysis by Quantity One Analysis Software (Bio-Rad, USA). Protein levels of cytochrome c, total Akt, and p-Akt were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels.
Determination of caspase-3 and caspase-9 activities
Proteins from the myocardial left ventricular cytosolic fraction were measured by a protein assay kit (BioTeke, China) according to manufacturer's protocol. Supernatant containing 100 µ g of protein was loaded and incubated with 20 µ g caspase-3 substrate (Ac-DEVDpNA) and caspase-9 substrate (Ac-LEHD-pNA) for 60 min at 37°C, respectively. The free pNA can be quantified using a microplate spectrophotometer (BioTeke, USA) at 405 nm. Results were calculated using a standard pNA curve and expressed as µ mol pNA/mg protein.
Statistical analysis
Data are mean ± S.D. In the animal study, one-way ANOVA was used to analyze differences by SPSS 11.0 software. P < 0.05 was considered significant.
Results
The effect of GXII on MBF
There were no differences in MBF between ischemic and non-ischemic zones, and between sham-operated and vehicle groups at the acute ischemic stage of MI (Table 1) , which is consistent with the literature (Boudina et al. 2002) . After chronic administration of GXII, MBF of the ischemic zone in MI rats was not significantly changed, when compared with the vehicle group.
The effect of GXII on myocardial infarct size
Effects of the vehicle control and GXII-treated groups on 24-h myocardial infarct size are shown in Fig. 1 . AAr was expressed as the percentage of Lv (AAr/Lv), and An was expressed as the percentage of AAr (An/AAr). There were no significant differences in AAr/Lv among the groups. Administration of GXII (2.5 g/kg) significantly reduced myocardial infarct size (An/AAr) compared with the vehicle group (32.69 ± 12.01% versus 48.24 ± 13.44%, p < 0.05). There was also a significant difference between the 2.5 g/kg group and the 0.5 g/kg GXII groups.
The effect of GXII on cardiomyocytes apoptosis
The apoptotic index (%) was measured in cardiomyocytes (Fig. 2) . Total nuclei were labeled with DAPI (blue), and apoptotic nuclei were detected by TUNEL staining (green). Heart tissue from sham-operated rats exhibited a very low level of staining for TUNEL. A significant num- Table 1 . Effects of 2.5 g/kg Guanxin II on myocardial blood flow of rats.
Group
Myocardial blood flow (mL/g/min)
Risk area Control area
Sham MI (n = 10) 3.64 ± 1.20 3.70 ± 1.29 MI + Vehicle (n = 10) 3.51 ± 1.42 3.49 ± 1.53 MI + 2.5 g/kg Guanxin II (n = 10) 3.62 ± 1.56 3.46 ± 1.41 Fig. 1 . Effect of GXII on 24-h myocardial infarct size. The percentages of AAr/Lv and An/AAr were determined respectively. Treatment with GXII (2.5 g/kg) could reduce myocardial infarct size. *p < 0.05 versus vehicle group (n = 6 rats/group).
ber of TUNEL-positive cells were detected in the ischemic tissue of the control group. GXII (2.5 g/kg) reduced the percentage of TUNEL-positive cells compared with the vehicle group (44.34 ± 6.78% versus 63.09 ± 10.34%, p < 0.01). There was a significant difference between the 2.5 g/kg group and the 0.5 g/kg group.
The effect of GXII on Akt activation
The levels of total Akt and p-Akt were examined by immunoblotting, and Akt kinase activity was measured. No differences of total Akt were detected among groups (Fig. 3) . Acute MI resulted in a marked reduction in p-Akt kinase activity. Treatment with GXII at 2.5 g/kg, but not at 0.5 g/kg, was associated with increased p-Akt kinase activity, when compared with the vehicle group (0.97 ± 0.06 versus 0.64 ± 0.20, p < 0.01). This suggested that GXII (2.5 g/kg) inhibited ischemic myocardial apoptosis via the activated Akt-survival signaling pathway. There was a significant difference between the two dosage groups.
The effect of GXII on Bcl-2 family proteins
As shown in Fig. 4 , coronary occlusion obviously reduced Bcl-2 expression and increased Bax expression compared with the sham group. Treatment with GXII (2.5 g/kg) was associated with greater Bcl-2 expression and attenuated Bax expression relative to the vehicle group. Treatment with GXII at 2.5 g/kg resulted in a marked increase in the Bcl-2/Bax ratio compared with the vehicle group (0.93 ± 0.01 versus 0.66 ± 0.04, p < 0.01). There was a significant difference between the 2.5 g/kg group and the 0.5 g/kg group.
The effect of GXII on cytochrome c
As shown in Fig. 5 , pretreatment with GXII (2.5 g/kg/ day for 15 days) was associated with a reduced level of cytosolic cytochrome c (1.05 ± 0.08 versus 1.25 ± 0.04, p < 0.01) and increased level of mitochondrial cytochrome c (0.95 ± 0.15 versus 0.76 ± 0.05, p < 0.01) compared with the vehicle control. There was a significant difference between 2.5 g/kg and 0.5 g/kg.
The effect of GXII on caspase-3 and caspase-9 activation
As summarized in Fig. 6 , a 3-h acute MI period caused an increase in caspase-3 and caspase-9 activation when compared with sham-operated group. Pretreatment with GXII (2.5 g/kg/day for 15 days) resulted in a significantly reduction in activation of caspase-3 (40.16 ± 6.77% versus 47.59 ± 3.85%, p < 0.05) and caspase-9 (50.46 ± 4.66% versus 66.64 ± 5.82%, p < 0.01) compared with the vehicle group. There was a significant difference between the two dosage groups.
Discussion
Our studies suggest that the rats pretreatment with GXII in the 2.5 g/kg/day for 15 consecutive days induce a direct antiapoptosis. GXII ensures the survival of myocardium by enhancing the Akt-mediated antiapoptosis pathway. It significantly activated Akt kinase, tilted the balance of Bcl-2 family members toward an antiapoptotic state, inhibited mitochondrial cytochrome c release, reduced caspase-9 activation, and attenuated subsequent caspase-3 activation and postischemic myocardial apoptosis in rats. In addition, the result has demonstrated the obviously different cardioapoptotic effects between the two dosages (0.5 and 2.5 g/kg) in MI cardiomyocytes.
A large number of studies indicate that myocardial infarction after ischemia is caused by apoptosis (Zhao et al. 2008; ). Apoptosis is a modality of pro- Fig. 4 . Effect of GXII on Bax/Bcl-2 ratio after a 3-h ischemia.
(A) Bax and Bcl-2 were detected by immunohistochemical means in myocardial tissue using antibodies that selectively recognize Bax and Bcl-2. (B) Mean optical density was calculated. Treatment with GXII (2.5 g/kg) was associated with greater expression of Bcl-2 and attenuated Bax. **p < 0.01 versus vehicle group (n = 6 rats/group). grammed cell death and a common pathological feature in MI. Akt as a mediator of cell death could modulate apoptosis (Luo et al. 2003; Takatani et al. 2004) . Some studies have shown that the Akt activity transduces important cell survival signals in some cell types (Terada et al. 2001; Danciu et al. 2003; Mangi et al. 2003) . In the present study, pretreatment with GXII (2.5 g/kg) could significantly reduce the infarct size and TUNEL-positive cells, compared with rats receiving vehicle ( Fig. 1 and 2 ), whereas no noticeable effect was detected with GXII at 0.5 g/kg. It indicated that pretreatment with GXII in the daily dosages of 2.5 g/kg/day for 15 consecutive days could protect the heart against myocardial apoptosis in rats with MI. Meanwhile, occlusion of the left coronary artery lead to reduced Akt kinase activity. Pretreatment with GXII (2.5 g/kg/day for 15 days) significantly increased Akt kinase activity (Fig. 3) , implying the antiapoptotic mechanism of GXII is related to the Aktsurvival signaling pathway. Akt also may regulate the balance between pro-survival and pro-apoptotic signals by regulating the cellular localization of Bcl-2 family (Zha et al. 1996; Franke et al. 2003; Garofalo et al. 2008) . As shown in Fig. 4 , administered of GXII at 2.5 g/kg could upregulate the expression of the prosurvival protein Bcl-2, and downregulate the expression of the pro-apoptotic protein Bax.
Release of cytochrome c is regulated by the Bcl-2 family proteins (Reed 2000) , but Akt regulates the mitochondrial apoptotic machinery and prevents the release of cytochrome c from mitochondria (Datta et al. 1997 ). In the mitochondrial pathway, cytochrome c is released from mitochondria into the cytosol in cells undergoing apoptosis. In the study, GXII (2.5 g/kg) could markedly reduce mitochondrial cytochrome c release from the mitochondria to the cytosol in MI cardiomyocytes (Fig. 5) .
Activated Akt kinase could be phosphorylated in suppressing apoptosis by modulating the activities of caspase (Takatani et al. 2004) ; conversely, the release of cytochrome c from the mitochondrion led to alteration of caspase activation (Reed 2000) . Our present study showed the activations of caspase-9 and caspase-3 in the vehicle control group has a significant increase compared to the sham-operated control group, and pretreatment with GXII (2.5 g/kg) was associated with enhanced their activations compared with the vehicle control group.
Meanwhile, pretreatment of GXII (2.5 g/kg) reduced apoptosis without increasing MBF (Table 1) , indicating it direct action on cardiomyocytes. The "direct" antiapoptosis was different from our previous "indirect" pathway in which GXII increased MBF following oral GXII (30 g/kg) to rats ). Altogether, the study showed GXII (2.5 g/kg/day for 15 days) induced a direct antiapoptosis by activated Akt kinase, further directly inhibited myocardial cell apoptosis via Bcl-2 family and mitochondrial cytochrome c-mediated caspases pathway.
During the clinical trials, GXII could also lead to sideeffects. The most frequently reported treatment-related adverse events were dry mouth, gastric upset, constipation, and dry stool (Xu et al. 2001) . Thus, we concluded that low-dose therapy of GXII was relatively safe and effective for long-term treatment. Our studies suggest that the rats' pretreatment with GXII (in the daily dosages of 2.5 g/kg/ day for 15 consecutive days) ensures the survival of myocardium.
In conclusion, GXII (2.5 g/kg/day for 15 consecutive days) significantly reduced infarct size, markedly decreased myocardial apoptosis. Furthermore, pretreatment with GXII significantly activated Akt kinase, increased the Bcl-2/Bax ratio, inhibited cytochrome c release, reduced caspase-9 activation, and attenuated subsequent caspase-3 activation. In addition, GXII did not change MBF of ischemic zone, indicating GXII direct action on cardiomyocytes. These results suggest that GXII ensures the survival of myocardium by enhancing the Akt-mediated antiapoptosis pathway. These findings provide the evidence for the effective and safe therapy with GXII for patients with chronic coronary heart disease.
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